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INTRODUCTION
Cryopreservation of tissue at –70°C to –196°C
offers the prospect of virtually indefinite storage.
Improvements to the preservation techniques, such
as the introduction of cryoprotectant agents and a
controlled rate of freezing, have enabled the devel-
opment of human blood vessel banks. 
Cryopreserved allogenic saphenous veins1 and
human femoral arteries (HFAs)2,3 are used for the
bypass of diseased peripheral arteries and the treat-
ment of limb-threatening ischemia or infected grafts.
The reactivity of human saphenous veins has been
extensively studied on both unfrozen and cryopre-
served tissues.4–8 However, no data exists concern-
ing the in vitro reactivity of HFAs, whereas the
arteries appear considerably more susceptible to
cryoinjury than the veins.6 The responses to various
contracting and relaxing agents of both unfrozen
HFAs and HFAs cryopreserved for 7 days and 30
days was assessed. The harvesting, freezing, and
thawing procedures were those routinely applied to
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HFAs that are to be transplanted as allografts. The
HFAs were stored at –141°C in Elohes solution
containing dimethyl sulfoxide (DMSO).
MATERIALS AND METHODS
Human femoral arteries preparation and stor-
age method. Samples of HFAs were carefully har-
vested from 9 multiorgan donors after permission
was obtained from the local ethical committee. The
tissues were immediately placed in Belzer solution at
+4°C for 4 to 36 hours.
The Belzer solution (ViaSpan) had the following
composition (mmol/L): hydroxyethylstarch (5.0),
lactobionic acid (100.0), KHPO3 (28.5), MgSO4, 7
H2O (5.0), raffinose pentahydrate (30.0), adenosine
(5.0), allopurinol (1.0), total glutathione (3.0),
KOH q.s., NaOH adjusted to pH 7.4. The femoral
arteries were then cut into 3 equal segments approx-
imately 3 cm long and were randomly divided into 3
groups. The control group (D0) consisted of fresh,
“unfrozen” HFAs that were transferred to the labo-
ratory for organ bath studies. The 2 cryopreserved
groups were stored at –141°C in gas nitrogen for 7
days (D7) or 30 days (D30). In both cryostored
groups, individual arterial segments were first trans-
ferred in Elohes solution (hydroxyethylstarch
200,000 [0.3 mmol/L], sodium chloride [15.4
mmol/L]) and then progressively loaded with
DMSO in 3 concentration steps (4%, 9%, and 14%
[weight/weight]), each lasting 2 minutes. The seg-
ments were stored in separated cryotubes containing
2 ml of the Elohes solution containing DMSO 14%
(1.8 mmol/L) and were allowed to equilibrate at
4°C for approximately 30 minutes before their trans-
fer to an automatic freezing machine (minidigitcool
IMV, Bicef, France). The mean cooling rate was
about 1.6°C/min, until –141°C was reached. After
the predetermined period of cryostorage of 7 days or
30 days, individual blood vessel segments were
quickly thawed by means of total immersion of the
cryotubes in a water bath (41°C) for 2 minutes. 
Organ-bath technique. Immediately after thaw-
ing, the arterial segments were precisely cut into rings
5 mm long. The number of rings obtained from the
femoral artery segments varied from 4 to 6. The rings
were placed in a 10 mL organ bath filled with Krebs-
Henseleit solution (mmol/L: NaCl 118, KCl 4.7,
CaCl2 2.5, MgSO4 1, KH2PO4 1, glucose 11,
NaHCO3 25), which was continuously bubbled with
a gas mixture (95% O2/5% CO2) and maintained at
37°C. The arterial rings were suspended on wires; the
lower wire was fixed to a micrometer (Mitutoyo,
Japan), and the upper was attached to a force trans-
ducer (UF-1, Pioden, U.K.) through which changes
in isometric force were displayed on recorders (Linseis
200, Bioblock, France). After being cautiously
mounted on the wires to preserve the endothelium,
the rings were allowed to equilibrate unstretched for
15 to 30 minutes. A normalization procedure was
then performed to set the vascular rings under in vitro
stress comparable to the in vivo pressure, as previous-
ly reported.9,10 Briefly, the rings were progressively
stretched with the micrometer at intervals of 5 g to
determine the internal circumference (calculated from
the distance between the wires)-tension exponential
curve for each ring. When the transmural pressure on
the rings reached 100 mm Hg, this stretch procedure
was stopped, and the rings were then released to
approximately 90 of their internal circumference at
100 mm Hg (0.9 D100). The isometric force at this
setting is the “passive” or “resting” force in the
absence of constrictor tone. This normalized degree
of stress was then maintained throughout the experi-
ment. Internal diameters at a pressure of 100 mm Hg
and the resting forces at 0.9 D100 were recorded.
PROTOCOL
After the normalization procedure, the arterial
rings were allowed to equilibrate for 60 minutes. The
rings were then contracted with KCl 90 mmol/L,
rinsed with Krebs solution, and allowed to equili-
brate for 1 hour. This initial maximal contraction was
performed to stabilize the preparations and to ensure
reproducible contractile responsiveness. During all
the equilibration periods, the Krebs solution was
changed every 15 minutes.
Thereafter, concentration-response curves were
established by cumulative addition of increasing 
concentrations (0.5-log increments) of the drugs, the
following concentration being added when the maxi-
mal effect had been produced by the previous con-
centration. Concentration-contraction curves were
established for the following ranges of concentrations
of contracting substances: KCl (7.5-120 mmol/L),
thromboxane A2 (TXA2)-mimetic U46619 (1
nmol/L-3 m mol/L), norepinephrine (1 nmol/L-100
m mol/L), 5-hydroxytryptamine (5-HT) (1 nmol/L-
100 m mol/L), and endothelin-1 (1 nmol/L-0.3
m mol/L).
When relaxing agents were investigated, the rings
were precontracted with 30 mmol/L KCl. Endo-
thelium-independent relaxations were assessed by
establishing concentration-relaxation curves for the
following ranges of concentrations of relaxing sub-
stances: sodium nitroprusside (SNP) (1 nmol/L-100
m mol/L), forskolin (1 nmol/L-30 m mol/L), and ver-
apamil (1 nmol/L-30 m mol/L). Endothelium-
dependent relaxation was assessed by measuring relax-
ation to acetylcholine (1 m mol/L)11. After the maxi-
mal effect of each drug was obtained, papaverine (300
m mol/L) was added to determine the maximum
relaxation achievable. On each arterial ring, only one
contracting agonist was tested, followed by investiga-
tion of one relaxant compound.
DATA ANALYSIS
Contractions are expressed as grams of isometric
force developed by the arterial rings in response to
the contracting agonists. Relaxation elicited by
papaverine (300 m mol/L) was considered 100%
relaxation. Endothelium-dependent relaxations and
smooth muscle-dependent relaxations are expressed
as percentages of the maximal relaxations achieved
with papaverine. The smooth muscle-dependent
relaxations were compared by determining the con-
centration (IC40) of agonist producing 40% of this
maximal papaverine-response.
Maximum effect (Emax) was the greatest
response obtained with an agonist. For the vasocon-
strictor agonists studied, the effective concentration
of substance that caused 50% of the maximal
response (EC50) was determined from each curve by
a logistic, curve-fitting equation. The pD2 value rep-
resents the negative logarithm of EC50.
Drug concentrations are expressed as final molar
concentrations in the organ bath. Data are given as
mean ± SEM. Statistical analysis was performed
using one-way analysis of variance (ANOVA) for
multiple comparisons, followed by Bonferroni cor-
rected t-test and individual comparisons were made
by Student’s t-test for paired or impaired data.
P<.05 was considered to be significant.
Drugs. TXA2 stable mimetic U46619 (9,11-
dihydroxy-11, 9-epoxy-methanoprostaglandin F2),
sodium nitroprusside (sodium nitroferricyanide), 5-
hydroxytryptamine (5-hydroxytryptamine hydrochlo-
ride), papaverine, and forskolin were obtained from
Sigma (L’isle d’Abeau, France); norepinephrine bitar-
trate was obtained from Assistance Publique des
Hôpitaux de Paris (France); endothelin-1 was
obtained from Euromedex (Souffelweyersheim,
France); KCl Normapur was obtained from Prolabo
(Paris, France); verapamil was obtained from Knoll
(Levallois Perret, France); Elohes solution was
obtained from Fresenius (Louviers, France); and
Belzer solution (ViaSpan) was obtained from Dupont
(Herts, Netherlands).
All drugs were dissolved in distilled water, except
forskolin, for which a stock solution at 100 m mol/L
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was prepared in DMSO. Drugs were kept at –20°C
and were freshly dissolved in distilled water to the
appropriate final concentrations.
RESULTS
Resting vessel parameters of the femoral
arteries. One hundred eleven femoral arterial rings
taken from 9 multiorgan donors were used. The
mean internal diameters at an equivalent transmural
pressure of 100 mm Hg were 5.3 ± 0.5 mm (D0),
5.1 ± 0.3 mm (D7), and 4.5 ± 0.4 mm (D30), and
the resting forces at 0.9 D100 were 17.0 ± 1.0 g
(D0), 16.8 ± 0.6 g (D7), and 15.8 ± 0.7 g (D30).
No statistically significant difference was found
between the resting vessel parameters of unfrozen
and cryopreserved arteries. The relations between
resting force and vessel internal diameter are shown
in Fig. 1.
Contractile responses. The contractile force as
assessed by the maximal response in grams of the
HFAs rings was markedly reduced in preparations
from frozen/thawed arteries. In fresh HFAs, the
maximal contractile response was diminished up to
34% for KCl (Fig. 2, A), up to 23% for U46619
(Fig. 2, B), up to 7% for norepinephrine (Fig. 2, C),
up to 13% for 5-HT (Fig. 2, D), and up to 23% for
endothelin-1 (Fig. 2, E). Nevertheless, KCl,
endothelin-1, and U46619 (at day 30) stimulated
the fresh and frozen/thawed arteries with similar
Fig. 1. Resting force-internal diameter relationships for
rings of fresh human femoral arteries (solid circle, n = 12)
and of human femoral arteries cryopreserved for 7 days
(open circle, n = 12) and for 30 days (open box, n = 12).
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Fig. 2. Cumulative concentration-contractile response curves on rings from unfrozen (solid
circle) and frozen/thawed for 7 days (open circle) or 30 days (solid triangle) human femoral
arteries in response to KCl (A), U46619 (B), norepinephrine (C), 5-HT (D), and endothelin-
1 (E). Results are expressed as gram force developed by ring vessels. The vertical bars repre-
sent mean ± SEM of 4 to 7 experiments.
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potencies. However, the apparent pD2 values were
significantly reduced at day 7 for U46619 and at
both day 7 and day 30 for norepinephrine and 5-HT
(Table I). 
In terms of maximal contraction and potency for
all these contracting agents, there was no significant
difference between HFAs cryopreserved for 7 days
or those cryopreserved for 30 days.
Endothelium-independent relaxant responses.
Relaxant responses to various agents, known to act at
the vascular smooth muscle through different mecha-
nisms, were investigated on fresh and frozen/thawed
HFAs rings that had been precontracted with KCl 30
mmol/L. In preliminary experiments, it was observed
that the maximal relaxation induced by papaver-
ine (300 m mol/L) was unchanged in fresh and
frozen/thawed arteries. The magnitude of the relax-
ations induced by papaverine, expressed as a percent-
age of the active tone induced by KCl, was 148 ± 12%
(n = 16) in D0, 182 ± 16% (n = 14) in D7, and 184 ±
28% (n = 12) in D30. Therefore, the responses 
to forskolin, verapamil, and SNP in fresh and
frozen/thawed arteries were expressed as a percentage
of the maximal relaxation elicited by papaverine.
Verapamil (Fig. 3, A) and forskolin (Fig. 3, B)
elicited similar relaxant responses from both fresh
and cryopreserved arteries. The –log IC40 values and
maximal responses were not statistically different in
fresh and frozen/thawed femoral arteries (Table II).
In contrast, marked differences of both potency
(expressed as –log IC40) and efficacy between fresh
and frozen/thawed arteries were observed when
SNP-induced relaxation was investigated (Fig.3, C;
Table II). In terms of maximal relaxation and poten-
cy for all these relaxant agents, there was no signifi-
cant difference between cryopreserved HFAs for 7
or 30 days.
Endothelium-dependent relaxant responses.
Endothelium-dependent relaxations were investigat-
ed on fresh and frozen/thawed HFAs precontracted
with 30 mmol/L of KCl. Acetylcholine (1 m mol/L)
induced a relaxant response in fresh HFAs that
reached 40 ± 11% (n = 8) of the maximal relaxation
elicited by papaverine, whereas arteries cryopre-
served for 7 or 30 days failed to relax in response to
acetylcholine.
Duration of storage at +4°C and recovery
after cryopreservation. The duration of storage at
+4°C in Belzer solution of the HFAs before cryop-
reservation varied from 4 to 36 hours. The relation-
ship between the time of cold storage and the post-
thaw functional recovery has been evaluated in terms
of both recovery of contractile response to the dif-
ferent vasoconstrictors tested (Fig. 4, A) and recov-
ery of endothelium-independent relaxant response
to SNP (Fig. 4, B and C). No relationship was found
between the time of cold storage in Belzer and the
reduction in these 2 types of response in the
frozen/thawed femoral arteries.
DISCUSSION
Cryopreserved human arteries are used for the
bypass of diseased peripheral arteries, and cryopre-
served femoral arteries have been used for the treat-
ment of limb-threatening ischemia2 or infection of
arterial bypass grafts.3 It was therefore important to
evaluate the functional alteration resulting from
cryostorage. Our study is the first to compare the
contractile responses as well as the endothelium-
dependent and endothelium-independent relaxant
Table I. Responses to contractile agents of unfrozen controls and human femoral arteries cryopreserved
for 7 (D7) or 30 days (D30)
Unfrozen Frozen/Thawed
D0 D7 D30
U46619 pD2 8.7 ± 0.4 7.7 ± 0.4* 8.2 ± 0.4
Emax (g) 24.2 ± 5.0 12.7 ± 1.4* 8.3 ± 1.3*
KCl pD2 1.9 ± 0.2 1.7 ± 0.0 1.6 ± 0.1
Emax (g) 14.1 ± 3.0 3.3 ± 0.8* 4.6 ± 2.4*
Norepinephrine pD2 6.1 ± 0.1 5.7 ± 0.1* 5.3 ± 0.4*
Emax (g) 22.5 ± 4.2 3.6 ± 1.6* 1.6 ± 0.5*
5-HT pD2 7.5 ± 0.3 6.4 ± 0.8* 5.4 ± 0.2*
Emax (g) 17.8 ± 4.5 3.2 ± 1.1* 2.3 ± 0.7*
Endothelin-1 pD2 7.8 ± 0.2 7.5 ± 0.4 7.6 ± 0.4
Emax (g) 21.3 ± 2.2 4.9 ± 2.0* 5.9 ± 0.4*
Emax = maximal contraction expressed as gram isometric force developed by the rings.
pD2 = –logEC50, negative logarithm of the molar concentration producing 50% of maximal response. Data are given as means ± SEM
of 4 to 7 experiments. 
*Significant differences (P<.05) against values determined in unfrozen controls. No significant difference was observed between HFAs
cryostored for 7 or 30 days.
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responses of both unfrozen and cryopreserved HFAs.
The resting vessel parameters (internal diameter
at an equivalent transmural pressure of 100 mm Hg
and resting force) were similar in unfrozen and
frozen/thawed HFAs, allowing a comparison of the
responses with vasoactive agents at a comparable
basis. In addition, the resting force-internal diameter
relationship was the same for both frozen and cryo-
preserved HFAs, suggesting that the passive
mechanical properties of the HFAs were not altered
by cryopreservation. This assumption is in agree-
ment with the results of previous studies in which
mechanical testing with a traction-compression
apparatus12,13 and viscoelastic properties evaluation
with a mock circulation loop14 showed that cryo-
preservation does not alter the mechanical and vis-
coelastic characteristics of human descending tho-
racic aorta12,13 and superficial femoral artery14.
Cryopreservation was associated with a marked
reduction of the contractility. The maximal contrac-
tile responses were in the range of 7% to 34% of the
responses in unfrozen HFAs with the different
receptor-mediated stimuli and also with KCl, which
provokes a contraction strictly dependent on Ca2+-
influx through voltage-operated channels. A reduc-
tion of the post-thaw contractility to less than 40%
of fresh tissue has been observed in human coro-
nary,15 internal mammary,16 and postmortem basilar
arteries,17 whereas the maximal response to norepi-
nephrine was only reduced to 75% in human pul-
monary arteries.18 Freezing of vascular preparations
generally results in a loss of contractile responsive-
ness.17,19 A post-thaw contractile force of about 60%
to 80% of the maximum achieved in fresh tissue has
been obtained following cryopreservation of animal
arteries,19–21 although post-thaw recoveries of less
than 50% have also been reported.22,23 In addition,
Ku et al.15,20 have shown that an identical cryo-
preservation procedure applied to canine and human
coronary arteries resulted in a greater loss of con-
tractility in human arteries, indicating vessel to ves-
sel variability in the susceptibility to cryoinjury. 
In contrast with the considerable reductions of the
maximal contractile responses, potencies in terms of
apparent pD2 values for KCl and endothelin-1 were
not altered, and values for U46619, norepinephrine,
and 5-HT were only moderately diminished after the
cryopreservation procedure. These results are in line
with previous studies showing that the sensitivities of
human arteries and veins and animal blood vessels for
various contracting agonists were well-maintained
after cryopreservation.4,16,18,20,21,23–25
In addition, the endothelium-independent relax-
ant responses appear weakly altered by the cryo-
preservation procedure. The relaxations induced by
forskolin, which acts through direct activation of
adenylate cyclase, and by verapamil, which acts
through calcium channel blockade, were similar in
fresh and cryopreserved HFAs. However, the cryo-
preserved HFAs were less sensitive than fresh HFAs
to the relaxant effect of SNP, which acts through
direct activation of guanylate cyclase. A decrease in
responsiveness to nitric oxide was previously reported
in canine saphenous graft after cryopreservation.25
Moreover, cryopreserved human coronary arteries
were recently reported to be significantly less sensitive
to SNP than unfrozen tissues, whereas a slight,
although nonsignificant, supersensitivity to SNP was
observed in cryopreserved human mesenteric arter-
ies.26 These results suggest that the cyclic guanosine
monophosphate (cGMP)-dependent pathway of
relaxation is susceptible to alteration by the cryop-
reservation process and that the development of
supersensitivity or hyposensitivity to nitrovasodilators
is tissue-specific. After cryoconservation, a weaker
sensitivity has also been reported for potassium chan-
Table II. Responses to relaxant agents of unfrozen controls and human femoral arteries cryopreserved for
7 (D7) or 30 days (D30)
Unfrozen Frozen/Thawed
D0 D7 D30
SNP –log IC40 8.1 ± 0.1 6.3 ± 0.4* 5.4 ± 0.4*
Emax 93.5 ± 1.9 79.3 ± 4.6* 65.0 ± 6.5*
Forskolin –log IC40 6.1 ± 0.4 5.3 ± 0.2 5.3 ± 0.2
Emax 75.3 ± 10.5 73.1 ± 5.7 65.6 ± 9.7
Verapamil –log IC40 6.8 ± 0.2 6.9 ± 0.2 6.5 ± 0.3
Emax 75.4 ± 7.3 91.9 ± 2.8 83.8 ± 4.8
Emax = maximal relaxation expressed as percentage of maximal response to papaverine 300 m M. IC40 are expressed as the molar con-
centration producing 40% of relaxation. Data are given as means ± SEM of 4 to 7 experiments. 
*Significant differences (P<.05) against values determined in unfrozen controls. Statistical analysis of the IC40 was performed on the –log
IC40. No significant difference was observed between HFAs cryostored for 7 or 30 days.
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nel activators in human pulmonary arteries18 and for
isoproterenol in human coronary arteries.15 Again, an
identical cryopreservation procedure applied to
canine and human coronary arteries resulted in a
reduction of the relaxant response to isoproterenol in
human arteries, whereas the response was well-pre-
served in canine arteries.15,20 In contrast to the
marked reduction of the maximal contractile respons-
es, the maximal relaxant responses were not altered or
were altered much less after cryoconservation.15,20–22
Fig. 3. Cumulative concentration-relaxant response curves on rings from unfrozen human
femoral arteries (solid circle) and human femoral arteries frozen/thawed for 7 days (open cir-
cle) or 30 days (solid triangle) for verapamil (A), forskolin (B), sodium nitroprusside (C).
Results are expressed as percentages of the maximal relaxation induced by papaverine 3.10-4
M. The vertical bars represent mean ± SEM of 4 to 6 experiments.
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Cryostorage of HFAs resulted also in a loss of the
endothelium-dependent relaxant response to acetyl-
choline. The alteration of the cGMP-dependent path-
way of relaxation may, at least in part, account for this
result because acetylcholine induced an endothelium-
dependent relaxation by stimulating the production
and release of nitric oxide from the endothelial cells,
which, in turn, induces the relaxation of the vascular
smooth muscle through the cGMP-dependent path-
way.27 However, the loss of the endothelium-depen-
dent relaxation may also be caused by alterations of
the cryostored HFAs endothelial cells. An incomplete
preservation of the vascular smooth muscle cell
response and of the endothelial cell function have
been previously evoked to explain the reduction in the
endothelium-dependent relaxant responses to hista-
mine, thrombin, and substance P after cryopreserva-
tion of human coronary arteries.15 In addition, a
reduction in the endothelium-dependent relaxant
response to substance P and bradykinin has been
Fig. 4. Effect of the duration of storage at +4°C in Belzer solution on the functional recov-
ery of human femoral arteries cryopreserved for 7 or 30 days. A, Effect of the duration of stor-
age on the reduction of the maximal contractile response to U46619 (open circle), norepi-
nephrine (open box), 5-HT (crossed box), KCl (solid triangle), and endothelin-1 (open triangle).
B, Effect of the duration of storage on the reduction of the relaxant response to SNP as per-
centage of the reduction in the response to 10-5 M SNP (open circle). C, Effect of the dura-
tion of storage on the reduction of the relaxant response to SNP as log-shift to the right of the
concentration-response (C/R) curve to SNP (open circle).
reported after cryopreservation of human mesenteric
and coronary arteries.26 However, retention of
endothelium-dependent relaxant responses and
endothelial release of prostacyclin have been demon-
strated following cryopreservation in human28 and
canine23 internal mammary arteries, in canine coro-
nary arteries,20 and in human saphenous veins.5,29
Further experiments using other endothelium-depen-
dent relaxants (substance P, bradykinin) and a histo-
logic examination are required to better evaluate the
cryoinjury of the endothelium of HFAs.
Therefore, the cryopreservation method used in
this report provided a limited preservation of HFAs
contractility, a good preservation of the endotheli-
um-independent relaxation in response to verapamil
and forskolin, a reduced preservation of the SNP-
induced relaxation, and no apparent preservation of
the endothelium-dependent relaxation to acetyl-
choline. The vehicle solution for cryoconservation
contained DMSO (1.8 mmol/L) and a high-molec-
ular-weight polymer, hydroxyethylstarch, as cryopro-
tecting agents. Hydroxyethylstarch is the colloidal-
osmotic support of the University of Wisconsin solu-
tion for organ preservation and exerts a potent
cryoprotective effect.30 In most studies on the cryo-
preservation of blood vessels, DMSO was used at
concentrations in the narrow range of 11% to 16%,
ie, 1.4 to 2.0 mmol/L, and the equilibration times of
the tissues in DMSO varied from 10 to 60 min-
utes.5,7,15,20,29 With respect to the equilibration
times in DMSO, optimal post-thaw functional recov-
ery in terms of contractions and endothelium-inde-
pendent relaxations was obtained with canine
femoral arteries that had been frozen within 10 to 20
minutes of being placed in the cryomedium.21
Retention of endothelium function in human saphe-
nous vein5,29 and canine coronary arteries20 follow-
ing cryoconservation has been demonstrated after
equilibration times in DMSO of 10 or 30 minutes.
Moreover, the measure of the permeation kinetics of
DMSO in the rabbit carotid artery has shown 
that the times required for 95% and 99% equilibra-
tion at 2°C were 18 and 32 minutes, respectively.31
Therefore, the equilibration time of 30 minutes in
DMSO 1.8 mmol/L in this study does not appear to
be the cause of the weak post-thaw functional recov-
ery. However, we have not assessed the effect of 30
minute exposure to Elohes solution on the endothe-
lial and smooth muscle functions, and, therefore, we
cannot exclude the possibility that this short-term
exposure before cryopreservation may have influ-
enced the post-thaw functional recovery. In addition
to using the appropriate concentration of DMSO
and time to equilibration, an optimal rate of cooling
is also important. In a recent study, a cooling rate of
0.69°C/min was associated with a maximal post-
thaw recovery of the contractile response and of both
the endothelium-dependent and endothelium-inde-
pendent relaxant responses of the rabbit carotid
arteries, whereas a significant reduction of the post-
thaw recovery was observed for a cooling rate of
2.2°C/min.32 Thus, a slower cooling rate for HFAs
(0.69°C/min instead of 1.6°C/min) may provide
better preservation of endothelial and smooth cell
functions. In other respects, the duration of storage
did not appear to influence the functional recovery of
cryopreserved femoral arteries, because no statistical
difference was found between HFAs cryopreserved
for 7 days and those cryopreserved for 30 days. 
The thawing step is generally performed by plac-
ing the storage container in a 37°C to 42°C water
bath for 2 minutes, and then removing DMSO by
rinsing the blood vessels with appropriate solutions.
The removal of DMSO by a stepwise dilution proto-
col to avoid damage by osmotic shock has not been
shown to improve the post-thaw functional recovery
of blood vessels.19 The thawing procedure applied to
the HFAs was in line with the standard procedure
applied to blood vessels and was therefore probably
not responsible for the weak post-thaw functional
recovery of the cryopreserved HFAs. However, it
was reported recently that fractures in cryopreserved
arteries, which are a major barrier to surgical use, can
be prevented by warming slowly (< 50°C/min) until
–100°C is reached,33,34 suggesting the interest of a
more controlled thawing process. Although the
occurrence of fractures was studied, inspection by
naked eye did not identify the presence of fracture in
the 3 cm long segments of frozen/thawed HFAs.
In addition to the freezing/thawing process by
itself, tissue handling during surgery and time of cold
storage before cryopreservation may influence tissue
viability and post-thaw recovery. Short-term storage
(1 hour) of human saphenous veins in University of
Wisconsin solution (Belzer solution) has been
reported to markedly attenuate endothelium-depen-
dent relaxation to acetylcholine and to increase
response to vasoconstrictors.35 The attenuation of
the relaxation to acetylcholine was attributed to high
potassium content of the Belzer solution, which may
cause functional and morphologic damages to vascu-
lar endothelium.35 Sharp relaxations to acetylcholine
were observed in all the HFAs rings tested after stor-
age in Belzer solution, but alteration of the endothe-
lium cannot be ruled out in absence of control relax-
ations to acetylcholine before storage in Belzer solu-
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tion. In addition, storage of rat aortas or canine coro-
nary arteries at 4°C in University of Wisconsin solu-
tion for up to 24 hours has been shown to preserve
endothelial and vascular-smooth muscle func-
tions.36,37 However, cold storage for 48 hours in a
modified Ringer solution was associated with a
decrease of the contractile force of human mammary
arteries to KCl and norepinephrine.16 In the present
study, the delay between removal from the body and
cryostorage varied from 4 to 36 hours (median, 17.6
hours); however, only 1 HFAs was stored at +4°C for
more than 24 hours (ie, 36 hours). Furthermore, we
did not observe a relationship between the time of
cold anoxia in Belzer solution and functional recov-
ery of the cryopreserved arteries. In addition, a pre-
liminary study conducted on human internal mam-
mary arteries has shown that the contractile respons-
es to norepinephrine and U46619 were similar or
even increased in segments stored in Belzer solution
at +4°C for 24 hours instead of 2 hours (Emax
Norepinephrine: 4.3 ± 0.8 g [24 hours in Belzer, n =
4] vs. 3.6 g [2 hours in Belzer, n = 4]; Emax
U46619: 7.0 ± 1.1 g [24 hours in Belzer, n = 4] vs.
4.8 ± 0.8 g [2 hours in Belzer, n = 4]). These data
are in agreement with the results reported in human
saphenous veins by Anastasiou et al.35 Therefore, the
reduction of the post-thaw functional recovery of
cryopreserved HFAs appears to be more related to
the freezing/thawing process than to the time of
cold storage in Belzer solution.
In conclusion, allogenic human femoral arteries
banking using cryopreservation techniques has
enabled the availability of allografts. Despite certain
problems, such as reduced contractile forces and loss
of overall endothelial cell function, cryopreserved
human femoral arteries remain useful grafts for limb
salvage when autologous blood vessels are not suit-
able.2 It is possible that further refinements of the
present cryostorage methodology, such as a slower
rate of cooling and a more controlled stepwise addi-
tion of DMSO32 or a slower rate of thawing, might
allow better post-thaw functional recovery of HFAs.
However, it is not known whether optimum condi-
tions of cryopreservation of endothelium and
smooth muscle functions would affect the long-term
patency of cryopreserved HFAs allografts. 
We thank Mark Hunt for helping to translate the
manuscript.
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